Harrow announced “Vevye Access For All”—a new initiative that aims to reduce patient barriers to dry eye disease treatment. Harrow partnered with specialty pharmacy PhilRx to offer Vevye (cyclosporine ophthalmic solution) 0.1% for eligible patients at $59 per bottle. The goal is to offer patients the ability to start affordable treatment without delays in care, according to Harrow. Additional key benefits of the program include no required prior authorizations, no delay prescription processing, and a money-back guarantee.

Vevye Access For All is available across the United States. Physicians that would like to enroll their patients in the program should send Vevye prescriptions to PhilRx via their electronic medical records, and eligible patients will receive the discounted pricing and benefits through the pharmacy. Looking ahead, Harrow states they aspire to make this program available at all pharmacies nationwide.